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Background: 
Genetic variants linked to pathways related to vitamin D metabolism are 
associated with 25-hydroxyvitamin D (25[OH]D) serum levels in patients with 
MS. 25[OH]D levels were found to be inversely correlated with the cumulative 
number of newly active lesions (CNALES) in patients receiving interferon 
beta-1b in the BEYOND (Betaferon Efficacy Yielding Outcomes of a New 
Dose) trial in relapsing-remitting MS. 
Objectives: 
To examine the association of 25[OH]D levels with disease severity and 
activity in interferon beta-1b-treated patients in BEYOND and how these 
associations are modified by genetic variants related to vitamin D metabolism. 
Methods: 
For genome-wide association studies (GWAS), 662 patients with phenotypic 
and genotypic data available were split into three geographic regions to 
account for systematic differences in vitamin D levels. GWAS were conducted 
on imputed variants for each region separately, using ancestry components, 
sex, age, treatment, presence of anti-drug antibodies, and, where applicable, 
disease duration as covariates. Results were combined using fixed-effects 
pooled analyses and used for calculation of genomic inflation, followed by 
  
examination of candidate variants. Variables assessed for associations 
include baseline MSSS (MS severity score, EDSS adjusted for disease 
duration), T2 lesion volume, and cerebral volume as well as annualized 
relapse count, change in EDSS, CNALES and change in cerebral volume over 
the 2-3.5 year period of the study. Analyses were carried out with and without 
including 25[OH]D levels. 
Results: 
MSSS and T2 lesion volume at baseline and CNALES over the course of the 
trial were significantly associated with 25[OH]D levels. Two candidate variants 
were significantly associated with MSSS, rs6599638 in the gene C10orf88 
(p=0.0003) and rs2248359 in CYP23A1 (p = 0.002); the association of 
rs6599638 improved when 25[OH]D levels were accounted for (p = 0.00007). 
No significant interaction between either variant and 25[OH]D levels could be 
detected. Furthermore, no significant associations were found between 
candidate variants and T2 lesion volume or CNALES. 
Conclusions: 
MSSS at baseline of the BEYOND trial was associated with 25[OH]D levels. 
Significant associations between two candidate genetic variants linked to 
vitamin D metabolism and MSSS were identified. 25[OH]D levels had a 
significant effect on these models. These variants were not associated with 
disease progression during the trial. 
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